Neurolief Welcomes Dr. Owen Muir as Chief Medical Officer to Enhance Depression Treatment Solutions

Neurolief Appoints Dr. Owen Muir as Chief Medical Officer

Neurolief, a frontrunner in the field of brain stimulation aimed at mental health and neurological issues, has announced an exciting development in its leadership team. Dr. Owen Scott Muir has been appointed as the fractional Chief Medical Officer (CMO), positioning him to spearhead initiatives that will innovate treatment approaches for patients battling major depressive disorder.

Dr. Muir's credentials are impressive. He is a dual board-certified psychiatrist specializing in both general and child psychiatry. His understanding of complex mood disorders sets him apart, making him a valuable asset to Neurolief. Notably, Dr. Muir contributes as a Clinical Assistant Professor at the Menninger Department of Psychiatry and Behavioral Sciences, where he is deeply involved in psychiatric education and research, further enriching his expertise.

As a co-founder of Fermata, a medical practice focused on neuromodulation technologies, Dr. Muir has made strides in merging clinical practice with groundbreaking technology. His prolific work includes numerous scientific publications and conference presentations, along with acting as a strategic advisor in the medical field. This blend of experience in psychiatry and regulated medical devices provides Neurolief with credible leadership that aims to address significant unmet needs in mental health care.

CEO Scott Drees expressed confidence in Dr. Muir’s capabilities, stating, “His extensive expertise in brain stimulation therapies... aligns perfectly with Neurolief's mission.” Under Dr. Muir’s guidance, the company aims to successfully launch Proliv™Rx, a therapy that could revolutionize the treatment landscape for those who suffer from treatment-resistant depression (TRD). This groundbreaking solution has received FDA Breakthrough Designation, the first of its kind to provide at-home brain stimulation that has demonstrated success in clinical trials.

In his own words, Dr. Muir added, “I’ve long hoped for effective and accessible treatment options... I’m honored to work alongside Neurolief's exceptional team to bring Proliv™Rx to individuals living with treatment-resistant depression.” The enthusiasm reflects a shared vision of providing hope and relief for patients who have found little success with conventional antidepressants.

Understanding Proliv™Rx

Proliv™Rx stands out as a major advancement in non-invasive brain neuromodulation therapy. Unlike standard treatments, this innovative solution is designed to be used both in clinical environments and in the comfort of a patient's home. It utilizes three adaptive output channels that deliver precise electrical pulses, stimulating brain regions that play crucial roles in mood regulation.

What makes Proliv™Rx particularly revolutionary is its integration with a patient-friendly mobile app and a cloud-enabled data tracking system. This interconnected approach enables physicians to monitor patient progress remotely and analyze data for personalized treatment adjustments. The ultimate goal is to enhance therapeutic outcomes for patients grappling with depression.

About Neurolief

Neurolief is committed to pushing the boundaries of traditional mental health treatment. It was the first company to develop a non-invasive, multi-channel brain stimulation technology aimed at treating various neurological and mental health disorders. Its flagship therapy, Relivion®MG, is already approved across multiple regions, including the USA, Europe, and Japan, for migraine relief.

As Neurolief gears up for its next chapter with Dr. Muir at the helm of medical innovation, the mental health community eagerly anticipates the profound impact Proliv™Rx will have on the millions of individuals seeking effective solutions for their depressive disorders. For more information about Neurolief and their pioneering work, visit Neurolief's official website.